---
title: "Innovations in ATMP: State of the Art in 2026"
description: "A comprehensive overview of the state of the art in Advanced Therapy Medicinal Products (ATMPs) as of June 2026 — covering EU regulation, cutting-edge manufacturing, evolving quality standards, and the business strategies shaping the future of gene, cell, and tissue therapies."
url: https://qbdgroup.com/en/downloads/innovations-in-atmp-state-of-the-art-2026
type: "White paper"
language: en
published: 2026-06-03
author: "QbD Group"
category: "Regulatory Affairs"
publisher: "QbD Group"
citation: "QbD Group, \"Innovations in ATMP: State of the Art in 2026\", https://qbdgroup.com/en/downloads/innovations-in-atmp-state-of-the-art-2026"
---
# Innovations in ATMP: State of the Art in 2026
> A comprehensive overview of the state of the art in Advanced Therapy Medicinal Products (ATMPs) as of June 2026 — covering EU regulation, cutting-edge manufacturing, evolving quality standards, and the business strategies shaping the future of gene, cell, and tissue therapies.

## About this white paper

Advanced Therapy Medicinal Products (ATMPs) are reshaping modern medicine. Gene therapies, cell therapies, and tissue-engineered products are moving from experimental promise to commercial reality — and the regulatory, manufacturing, and commercial frameworks around them are evolving just as fast.

This white paper provides a **comprehensive overview of the state of the art in ATMPs as of June 2026**. It brings together the latest developments in EU regulation, breakthrough manufacturing technologies, updated quality standards, and the business strategies driving the sector forward. It is **essential reading for ATMP developers, CDMOs, regulatory professionals, and life science executives** navigating one of the fastest-moving fields in life sciences.

## What you'll learn

- How the **EU regulatory landscape for ATMPs** is evolving, including the new Biotech Act and updated GMP Part IV guidelines
- What **breakthrough manufacturing innovations** — from automated CAR-T platforms to digital twin technology — mean for ATMP production
- Why the **EU HTA Regulation** (in force since January 2025) is reshaping ATMP market access and reimbursement strategy
- How global **ATMP and CDMO markets** are growing, with projections reaching USD 245 billion by 2034
- What **business development strategies** — outcomes-based payment models, CDMO consolidation, automation — are key to commercial success
- How updated **Ph. Eur. monographs and the new EMA guideline on investigational ATMPs** affect clinical trial submissions

## Who should read this

- ATMP developers and sponsors planning EU clinical trials or commercial launches
- CDMOs scaling cell and gene therapy manufacturing
- Regulatory affairs and quality leaders responsible for ATMP compliance
- Business development and market access teams shaping ATMP commercial strategy
---
Source: https://qbdgroup.com/en/downloads/innovations-in-atmp-state-of-the-art-2026 — © QbD Group. Quote freely with attribution and a link back.